A weekend near-miss involving an antibiotic order at Harbor City Medical Center has prompted a hospitalwide refresher for nurses on how four everyday pharmacokinetic ideas show up in real patient care — and why they can make the difference between a drug that works, a drug that doesn’t, and a drug that harms.

Hospital officials said the patient, a 68-year-old man admitted for sepsis and kidney injury, was stable and suffered no lasting effects after a medication order was paused during a routine safety check on Saturday.

The order initially called for an oral antibiotic dose in a patient who was vomiting and on vasopressors, a situation nurses said often signals unreliable gut absorption.

“Everybody saw the same problem at the bedside: he wasn’t keeping anything down,” said charge nurse Lena Ortiz, who flagged the order before administration. “That’s not a ‘pharmacy’ issue. That’s a nursing assessment issue.”

The case became the first scenario discussed Monday morning in a packed in-service hosted by infectious-disease pharmacist Alan Bixby and ICU educator Tasha Nguyen.

Route matters when the gut can’t be trusted

Clinicians used the weekend case to talk through why an oral order can behave like an under-dose — or like nothing at all — in certain patients.

Bixby said the team’s first question was not the milligrams on the label, but whether the medication would reach the bloodstream in a meaningful amount.

“Some drugs lose a chunk of the dose before it ever gets to systemic circulation,” Bixby told the group, describing what staff commonly call “first-pass” effect. “And even before that, the gut has to be working.”

Nguyen said the patient’s persistent emesis and poor perfusion created two red flags nurses recognize: pills coming back up, and a GI tract that may not be getting enough blood flow.

On the unit’s whiteboard, educators summarized the conversation in bedside terms, using bullet points that nurses later photographed:

• If a patient can’t tolerate oral meds (vomiting, continuous suction, severe diarrhea), then expect unpredictable benefit and consider IV alternatives early.
• If a drug is known for heavy “first-pass” loss, then the oral form may feel “weaker” than IV even when the dose looks big on paper.
• If the drug is given IV, then staff can assume the full dose reaches circulation immediately, making onset and effect more reliable.

The team ultimately switched the patient’s therapy to IV dosing, hospital officials said.

Where the drug “seems to be” can change what nurses see

The in-service moved from route to a second concept that often shows up as a bedside mystery: why some drugs appear to “vanish” from the bloodstream right after administration.

In the weekend case, a separate discussion involved a colleague’s suggestion to “just give a bigger first dose” of a different agent because the initial levels drawn later were lower than expected.

“That instinct isn’t wrong,” Nguyen said. “But it has to be tied to where the drug is going.”

Educators described the clinical meaning of distribution using a metaphor heard frequently in nursing report: “Is the drug staying mostly in the blood, or is it leaving the bloodstream and parking in tissues?”

They framed the decision-making in “If…then…” statements tied to what nurses monitor:

• If a drug rapidly leaves the bloodstream and spreads into body water or tissues, then early blood levels may look low even when the dose was given correctly.
• If the goal is to reach an effective concentration quickly in a seriously ill patient, then a clinician may order a larger first dose (a “loading” approach) to fill that tissue space sooner.
• If a patient has significant fluid shifts (edema, third-spacing, ascites), then a “usual” first dose may look slow to work, and the team may reassess early response and timing of levels.

Bixby cautioned that a bigger first dose is not a shortcut for all patients. “It’s not about chasing a number,” he said. “It’s about reaching the site of action without overshooting into toxicity.”

Clearance shows up as a kidney story — and a maintenance story

The weekend case also involved a lab trend nurses see daily: rising creatinine.

For ICU nurse Ortiz, the turning point came when she noticed the patient’s urine output dropping and asked whether the antibiotic order had been adjusted for kidney function.

“That’s not me trying to practice pharmacy,” Ortiz said afterward. “That’s me looking at the Foley bag and the labs and thinking: his body might not be able to get rid of this the way it did yesterday.”

In the in-service, educators described clearance in plain terms as the body’s capacity to remove a drug over time. They linked it to the everyday question nurses ask during handoff: “Will this build up?”

The unit’s “If…then…” list connected clearance to maintenance dosing choices:

• If kidney or liver function declines, then the body’s ability to remove many drugs declines, and routine doses can start acting like overdoses.
• If clearance is reduced, then the team may extend the interval, lower the dose, or both — and nurses may see prolonged sedation, hypotension, or “too much effect.”
• If clearance improves (diuresis, recovery from shock), then drug levels can fall sooner than expected, and nurses may see breakthrough pain, rising blood pressure, or return of fever.

Nguyen pointed to a pattern that often frustrates new staff: “The same dose that felt right on day one can be wrong by day three,” she said.

Half-life explains slow change, accumulation and when to expect steady results

The session’s final segment focused on what Nguyen called “the waiting game” — why some drug effects take days to settle, and why early dose changes can create whiplash later.

The educators did not write formulas, but they described a rule of thumb nurses can apply during daily assessments: many drugs take several half-lives to reach a stable, predictable level in the body.

“People want to fix the number today,” Bixby said, referring to drug levels and lab targets. “But some meds don’t cooperate with that timeline.”

They posted a practical bedside list:

• If a drug has a long half-life, then the effect changes slowly after a dose change, and early “not working” may be premature.
• If doses are given repeatedly before much drug has been removed, then the drug accumulates, and side effects may appear later even if the first few doses looked fine.
• If a team is waiting for a medication to “settle,” then expect that it often takes about four to five half-lives before levels and effects look steady.

Nguyen said nurses can use that timeline to set expectations for families and to frame when to escalate concerns. “If we’re still far from steady state and the patient is worsening, we don’t just wait,” she said. “We tell the provider what we’re seeing.”

A familiar example: vancomycin and gentamicin levels

To ground the concepts, educators used a case-based narrative involving vancomycin and gentamicin, two antibiotics often tied to therapeutic drug monitoring.

Bixby described a hypothetical patient with a bloodstream infection who receives vancomycin, then has fluids started aggressively for hypotension.

“In that patient, the first level can surprise you,” he said. “You may have a drug that distributes widely in body water, and now the water has changed.”

He also described the opposite scenario: an older patient on gentamicin whose kidney function worsens overnight.

“Suddenly the body’s removal capacity is smaller,” he said. “If you don’t adjust, you can walk into toxicity.”

Nurses were encouraged to connect monitoring to the four themes:

• If the drug is given IV and the level is still low, then think beyond “missed dose” — consider distribution, fluid shifts, and timing of the draw.
• If a patient’s creatinine rises or urine output falls, then expect slower removal and advocate for reassessment of dosing and timing of levels.
• If dizziness, ringing in the ears, or worsening kidney markers appear during therapy, then communicate early, since accumulation can show up after several doses.

Warfarin vs. heparin: why onset can look so different

The in-service also revisited anticoagulation, a topic that Nguyen said often leads to misunderstandings about “fast” and “slow” drugs.

In a vignette, a patient with a new clot is started on heparin in the hospital and warfarin for longer-term therapy.

“Heparin is like flipping a switch — you see the effect quickly, and you can stop it and watch it fade,” Nguyen said, describing why nurses can observe changes in bleeding risk and lab response over a short time.

Warfarin, she said, can feel like “steering a ship.” Nurses in the room nodded as she described the lag between the first dose and the full clinical effect.

The unit’s “If…then…” summary tied the observation to half-life and accumulation:

• If a medication’s effect depends on changing the balance of clotting factors over time, then the bedside effect may lag behind the first dose.
• If the team adjusts warfarin too aggressively early, then the patient may “look fine” for a day or two and then swing into a supratherapeutic effect later.

Hospital says refresher is part of safety push

Harbor City Medical Center spokesperson Janelle Price said the weekend pause followed standard verification steps and was reported internally as a near-miss.

“The outcome we want is a culture where nurses feel empowered to question route, timing, monitoring and dose when the clinical picture doesn’t match the order,” Price said.

Ortiz said the biggest takeaway for bedside staff was that pharmacokinetics isn’t abstract.

“It’s in the IV versus PO decision,” she said. “It’s in the edema, the creatinine, the timing of the lab draw. It’s in the fact that some meds don’t show their hand until days later.”

The hospital plans to repeat the training for medical-surgical units next month and to add scenario cards to medication rooms, Nguyen said.

“We want nurses to have language for what they already notice,” she said. “When the body changes, the drug’s behavior changes. Our job is to catch it early.”